Zentalis Pharmaceuticals, Inc.

Informe acción NasdaqGM:ZNTL

Capitalización de mercado: US$230.2m

Zentalis Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los beneficios de Zentalis Pharmaceuticals disminuyan en un 0.1% al año, mientras que se espera que sus ingresos anuales crezcan en un 37% al año. Se prevé que el BPA crezca en un 8.1% por año. Se espera que la rentabilidad financiera sea de -107.1% en 3 años.

Información clave

-0.1%

Tasa de crecimiento de los beneficios

8.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs28.3%
Tasa de crecimiento de los ingresos37.0%
Rentabilidad financiera futura-107.1%
Cobertura de analistas

Good

Última actualización15 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

May 09
Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

Recent updates

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully

Oct 03
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully

Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher

Jun 19
Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Jun 13
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

May 09
Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling

Apr 12

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Feb 29
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Zentalis: Leading WEE1 Developer After AstraZeneca's Exit

Feb 05

Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?

Jan 09
Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?

We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate

Oct 13
We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Jun 30
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Dec 01
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer

Sep 27

Zentalis Pharmaceuticals has a new chief medical officer

Sep 19

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Aug 17
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

May 02
Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Jan 12
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Oct 14
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Jul 02
Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

Mar 08
Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Jan 20
Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:ZNTL - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/202623-246-220-2688
12/31/2025N/A-233-194-2329
12/31/202441-173-169-17411
9/30/202441-179-172-172N/A
6/30/202441-195-167-166N/A
3/31/202441-219-211-211N/A
12/31/2023N/A-292-208-208N/A
9/30/2023N/A-286-205-205N/A
6/30/2023N/A-285-201-199N/A
3/31/2023N/A-241-165-163N/A
12/31/2022N/A-237-166-164N/A
9/30/2022N/A-232-168-163N/A
6/30/2022N/A-182-169-164N/A
3/31/2022N/A-168-173-167N/A
12/31/2021N/A-159-160-154N/A
9/30/2021N/A-149-149-144N/A
6/30/2021N/A-179-133-132N/A
3/31/2021N/A-152-109-107N/A
12/31/2020N/A-118-88-87N/A
9/30/2020N/A-92-73-73N/A
6/30/2020N/A-70-62-62N/A
3/31/2020N/A-53-47-47N/A
12/31/2019N/A-46-39-39N/A
12/31/20180-23-24-24N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ZNTL siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ZNTL siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ZNTL siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (37% al año) de ZNTL crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (37% al año) de ZNTL crezcan más rápidamente que un 20% al año.


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: ZNTL se prevé que no sea rentable en 3 años.


Descubre empresas en crecimiento